News & Press

Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
Non regulatory press release
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...
March 22, 2021
Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients
Non regulatory press release
GOTHENBURG, Sweden, March 22, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
March 22, 2021
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
Regulatory press release
GOTHENBURG, Sweden, March 19, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
March 19, 2021
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
Non regulatory press release
GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
January 15, 2021
Isofol reaches 440 patients in global Phase III AGENT study
Non regulatory press release
GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
December 09, 2020
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
Non regulatory press release
GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
November 02, 2020
Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
Regulatory press release
GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
November 02, 2020
55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study
Non regulatory press release
GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...
September 30, 2020
Strengthened patent protection for arfolitixorin in Japan
Non regulatory press release
GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...
September 01, 2020
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia
Non regulatory press release
GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
August 13, 2020
Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan
Regulatory press release
GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...
August 13, 2020
Isofol's CEO Ulf Jungnelius has subscribed for all warrants
Non regulatory press release
GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First...
August 04, 2020
A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis
Regulatory press release
GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First...
July 21, 2020
AGENT study update with regards to COVID-19
Non regulatory press release
GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...
July 10, 2020
Isofol’s rights issue oversubscribed
Regulatory press release
GOTHENBURG, Sweden, June 3, 2020 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...
June 03, 2020
Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson
Non regulatory press release
GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...
May 29, 2020
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million
Regulatory press release
GOTHENBURG, Sweden, May 14, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...
May 14, 2020
Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million
Regulatory press release
GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...
May 07, 2020
Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States
Regulatory press release
GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...
May 05, 2020
Information in relation to COVID-19
Non regulatory press release
GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...
April 02, 2020
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million
Regulatory press release
GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...
March 30, 2020
Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin
Non regulatory press release
GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...
March 30, 2020
The first patient included in Japan in Isofol's Phase 3 AGENT study
Non regulatory press release
GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...
February 18, 2020
Gene expression analysis method has been validated by a commercial laboratory
Non regulatory press release
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...
January 30, 2020
Over 200 patients now randomized in the Global Phase 3 AGENT Study
Non regulatory press release
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...
January 30, 2020
The Phase 1/2a study ISO-CC-005 is completed
Non regulatory press release
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...
January 30, 2020
The first patient included in Australia in Isofol's Phase 3 AGENT study
Non regulatory press release
GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...
January 24, 2020
Patent approved in Japan for Isofol’s drug candidate arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)....
December 20, 2019
Patent detecting how patients respond to folate-based cancer treatment approved in the USA
Regulatory press release
GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
December 13, 2019
Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia
Non regulatory press release
GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
November 18, 2019
Isofol's board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company
Regulatory press release
GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
November 13, 2019
Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
Non regulatory press release
GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
October 18, 2019
Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
Non regulatory press release
GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
September 29, 2019
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
Non regulatory press release
GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
September 12, 2019
Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer
Non regulatory press release
GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
August 15, 2019
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin
Non regulatory press release
GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
July 15, 2019
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
June 25, 2019
Isofol Announces Election of Three New Board Members
Non regulatory press release
GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...
June 10, 2019
Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States
Regulatory press release
GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
May 21, 2019
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today...
May 08, 2019
Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor
Non regulatory press release
GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
February 27, 2019
Isofol Reports All Employees Participate in Newly Created Share Warrant Program
Non regulatory press release
GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
February 01, 2019
Isofol has participated in the Empowered Patient Podcast
Non regulatory press release
In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO...
January 31, 2019
Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
January 17, 2019
First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer
Regulatory press release
GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...
December 18, 2018
Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development
Non regulatory press release
GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
November 19, 2018
Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors
Non regulatory press release
GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...
November 16, 2018
Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
Regulatory press release
GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...
November 15, 2018
New Chairman and extended board at Isofol Medical AB (publ)
Regulatory press release
Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling...
September 11, 2018
Patent approved in the United States for Isofol’s drug candidate arfolitixorin
Regulatory press release
The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical...
August 31, 2018